Chase Therapeutics Announces $20 Million Series B Financing to Advance Clinical Trials in Parkinson’s Disease and Major Depressive Disorder

WASHINGTON--(BUSINESS WIRE)--Chase Therapeutics Corporation, a Washington, DC based clinical stage pharmaceutical company, today announced the completion of a milestone-based $20M Series B financing led by Chinalink Asia Holdings of Hong Kong. This new round builds on the earlier financings from Brain Trust Accelerator Fund II of Burlingame, CA, and the...

Click to view original post